30 August 2016

VERONA PHARMA PLC - Data on RPL554 to be presented at ERS Congress

PR Newswire
London, August 29

Verona Pharma plc
("Verona Pharma" or the "Company")

New clinical data on RPL554 to be presented at the 2016 ERS International Congress

Detailed data from Phase 2a “add-on” trial as “LATE-BREAKING abstract”

30 August 2016, Cardiff - Verona Pharma plc (AIM: VRP.L), the drug development company focused on first-in-class medicines to treat respiratory diseases, today announces that it will present three abstracts at the European Respiratory Society (ERS) 2016 International Congress in London, UK between 3-7 September. The abstracts will cover clinical data related to the Company’s lead drug, RPL554, a novel inhaled dual PDE3/PDE4 inhibitor with both bronchodilator and anti-inflammatory properties. RPL554 is currently in development as a nebulised maintenance treatment for chronic obstructive pulmonary disease (COPD) patients with moderate to severe disease and as a treatment for acute exacerbations in COPD patients in a hospital or home-care setting.

Detailed results from the Company’s Phase 2a “add-on” trial, where RPL554 produced a statistically and clinically significant additional bronchodilation on top of standard of care bronchodilators in COPD patients, will be presented for the first time in an oral presentation, by Professor Dave Singh from the Medicines Evaluation Unit, University of Manchester, during a late-breaker session on Monday, 5 September 2016, at 11:00 in Room C.

All three abstracts presented at ERS support Verona Pharma’s view that RPL554 could become an important, novel and complementary inhaled medicine for the treatment of respiratory diseases such as COPD, asthma and cystic fibrosis. In summary, the detailed data supports previously announced analysis of headline data which identified:

- Profound and sustained bronchodilation in healthy volunteers, COPD patients and asthmatics;
- Comparable bronchodilation to high dose nebulised salbutamol (a standard of care treatment) in asthmatics with fewer systemic effects; and
- Statistically and clinically significant improvements in lung function when administered as “add-on” treatment to existing standard of care bronchodilators in COPD patients.

All abstracts and details on timings can be accessed through the ERS website: http://erscongress.org/

The title, timing and location of the abstract presentations are as follows:

**Abstract Number:** 750050

**Authors:** D. Singh, K.H. Abbott-Banner, K. Newman

**Title:** LATE-BREAKING ABSTRACT: The novel inhaled dual PDE3/4 Inhibitor, RPL554, produces significant additional improvements in lung function when administered on top of
existing standard of care in COPD patients

Day/Date: MONDAY, September 5, 2016
Location: Room C
Time: 10:45 - 12:45
Session: Late-breaking topics in airways disease
Session Type: Oral Presentation

Abstract Number: 851700
Authors: D. Singh, K.H. Abbott-Banner, K. Newman
Title: RPL554, an inhaled PDE3/4 inhibitor, causes profound and sustained bronchodilation in healthy volunteers and COPD patients

Day/Date: TUESDAY, September 6, 2016
Location: T-21
Time: 12:50 - 14:40
Session: Novel avenues in the treatment of COPD
Session Type: Thematic Poster Session

Abstract Number: 853133
Authors: L. Bjermer, J. Stewart, K. Abbott-Banner, K. Newman
Title: RPL554, an inhaled PDE3/4 inhibitor, causes comparable bronchodilation to high dose nebulised salbutamol in asthmatics with fewer systemic effects

Day/Date: WEDNESDAY, September 7, 2016
Location: Room ICC Capital Suite 8.
Time: 8:30 - 10:30
Session: Novel mechanisms and treatment modalities in asthma
Session Type: Poster Discussion

---ENDS---

About Verona Pharma

Verona Pharma plc is a UK-based clinical stage biotech company focused on the development of innovative prescription medicines to treat respiratory diseases with significant unmet medical needs, such as chronic obstructive pulmonary disease (COPD), asthma and cystic fibrosis.

Verona Pharma's lead drug, RPL554, is a first-in-class drug currently in Phase 2 trials as a nebulised maintenance treatment for COPD patients with moderate to severe disease and possibly as a treatment of acute exacerbations of COPD in the hospital setting. The drug is a dual phosphodiesterase (PDE) 3/4 inhibitor and therefore has both bronchodilator and anti-inflammatory effects, which are essential to the improvement of patients with COPD and asthma.

Verona Pharma is also building a broader portfolio of RPL554-containing products to maximise its benefit to patients and its value. This includes the very significant markets for COPD and asthma maintenance therapy. The Company is also exploring the potential of the drug in different diseases, such as cystic...
fibrosis, where it is in pre-clinical testing and has received a Venture and Innovation Award from the Cystic Fibrosis Trust.

About ERS

The European Respiratory Society (ERS; www.ersnet.org) is an international organisation that brings together physicians, healthcare professionals, scientists and other experts working in respiratory medicine. It is one of the leading medical organisations in the respiratory field, with a growing membership representing over 140 countries worldwide.

ERS’s mission is to promote lung health in order to alleviate suffering from disease and drive standards for respiratory medicine globally. Science, education and advocacy are at the core of everything it does.

THE 26th ERS International Congress will take place at London’s ExCeL Centre and will host the world’s largest and most influential meeting for respiratory physicians, scientists and allied health professionals. The Congress Scientific programme will present the best in science and educational sessions from distinguished researchers from across the globe. It will cover key topics in respiratory medicine from across the spectrum of disease areas including TB, lung cancer, pneumonia, cystic fibrosis, COPD and asthma amongst others.

Further information on the congress can be accessed via the following weblink: http://erscongress.org/

For further information, please contact:

Verona Pharma plc
Jan-Anders Karlsson, CEO
Tel: +44 (0)20 3283 4200

N+1 Singer
Aubrey Powell / Jen Boorer
Tel: +44 (0)20 7496 3000

FTI Consulting
Simon Conway / Stephanie Cuthbert / Natalie Garland-Collins
Tel: +44 (0)20 3727 1000

Verona Pharma plc
Jan-Anders Karlsson, CEO
Victoria Stewart, Director of Communications
Tel: +44 (0)20 3283 4200
info@veronapharma.com

N+1 Singer (Nominated Adviser and UK Broker)
Aubrey Powell / Jen Boorer / Iqra Amin (Corporate Finance)
Brough Ransom / Mia Gardner (Corporate Broking)
Tel: +44 (0)20 3283 4200

Optimum Strategic Communications
(European Media and Investor enquiries)
Mary Clark, Annemarieke Ezendam
Hollie Vile
Tel: +44 (0) 203 950 9144
verona@optimumcomms.com

Argot Partners (Investor enquiries)
Stephanie Marks
Tel. +1 646 644 9590
verona@argotpartners.com

About Verona Pharma plc
Verona Pharma is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapeutics for the treatment of respiratory diseases with significant unmet medical needs. Verona Pharma’s product candidate, RPL554, is a first-in-class, inhaled, dual inhibitor of the enzymes phosphodiesterase 3 and 4 that acts as both a bronchodilator and an anti-inflammatory agent in a single compound. In clinical trials, treatment with RPL554 has been observed to result in statistically significant improvements in lung function as compared to placebo
and has shown clinically meaningful and statistically significant improvements in lung function when added to two commonly used bronchodilators as compared to either bronchodilator administered as a single agent. RPL554 has also shown anti-inflammatory effects and been well tolerated in clinical trials. Verona Pharma is developing RPL554 for the treatment of chronic obstructive pulmonary disease (COPD), cystic fibrosis, and potentially asthma.

Forward Looking Statements
This press release contains forward-looking statements. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements.

These forward-looking statements are based on management's current expectations. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from our expectations expressed or implied by the forward-looking statements, including, but not limited to, the development of DPI and MDI formulations of RPL554 and the potential for these formulations to increase the market opportunity for the product, if approved.

These and other important factors could cause actual results to differ materially from those indicated by the forward-looking statements made in this press release. Any such forward-looking statements represent management's estimates as of the date of this press release. While we may elect to update such forward-looking statements at some point in the future, we disclaim any obligation to do so, even if subsequent events cause our views to change. These forward-looking statements should not be relied upon as representing our views as of any date subsequent to the date of this press release.